Physicians' Academy for Cardiovascular Education

Managing patients with hypertrophic cardiomyopathy: what is the therapeutic landscape?

Listen to the podcast
10' education - Sep. 30, 2022 - Prof. Iacopo Olivotto, MD - Florence, Italy

Video navigation menu

  • Current management options in HCM 00:43
  • Excessive actin-myosin cross-bridging in HCM 03:38
  • A cardiac myosin inhibitor targets the underlying pathophysiology of HCM 05:40
  • Results of clinical studies with the cardiac myosin inhibitor 08:00
  • Conclusions  11:42


Show transcript

Educational information

This lecture by Prof. Iacopo Olivotto was part of the EBAC-accredited symposium "Innovative therapeutic approaches in hypertrophic cardiomyopathy" held during the ESC congress 2022.


Prof. Iacopo Olivotto is Head of the Cardiology Unit at Meyer University Children Hospital and Professor of Cardiovascular Medicine at the University of Florence, Italy. His main clinical and research interests include various aspects of cardiomyopathies, with special focus on hypertrophic cardiomyopathy. Iacopo Olivotto is a co-founder and board member of The Sarcomeric Human Cardiomyopathy Registry (Share) and ICON (International CardiomyOpathy Network).


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.


Funding for this educational program was provided by an unrestricted educational grant from Bristol Myers Squibb.

View the slides of this presentation

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: